The ATLAS bioassay empirically identified both stimulatory and inhibitory tumor neoantigens: vaccinating with stimulatory ones protected mice, while inhibitory ones accelerated tumor growth — revealing a critical cancer vaccine safety concern.
99% antigen response + safety warningPersonalized vaccine using only ATLAS-verified stimulatory neoantigens achieved 99% immune response, while vaccinating with wrong neoantigens accelerated cancer
What the researchers found
ATLAS identified both stimulatory and inhibitory neoantigens. In B16F10 melanoma, stimulatory neoantigens protected while inhibitory ones accelerated tumor growth and abolished protective vaccine efficacy. Clinical trial: personalized vaccine well-tolerated, 99% antigen immune response rate.
Why it matters
Most neoantigen vaccine efforts use computational prediction alone. This study shows that some predicted neoantigens are actually harmful — making empirical testing essential for safe and effective personalized cancer vaccines.
The numbers in context
99% peptide antigen response rate; inhibitory neoantigens accelerated tumor growth; CD4+ and CD8+ responses generated
How the study worked
ATLAS bioassay: patient tumor mutations expressed in E. coli, pulsed on autologous DCs, tested against patient T cells. Mouse melanoma therapeutic vaccination. Clinical study interim analysis of poly-ICLC adjuvanted personalized neoantigen vaccine in adjuvant setting.
Who was studied
B16F10 murine melanoma; lung cancer patients (profiling); cancer patients (vaccine trial)
What this study cannot tell us
Interim clinical analysis (not final results). B16F10 mouse model may not represent all human cancers. ATLAS requires patient blood and tumor samples. The inhibitory mechanism is not fully understood. Time-intensive assay.
How to read the evidence
Moderate-to-high evidence: combined preclinical efficacy, mechanistic discovery (inhibitory neoantigens), and clinical trial interim data. Published in Cancer Discovery.
When this study was published
Published 2021. Neoantigen empirical testing is being adopted by several cancer vaccine programs.
The bigger picture
The discovery of inhibitory neoantigens fundamentally changes cancer vaccine design. It means simply including all mutations in a vaccine is dangerous — careful empirical screening is needed to include only beneficial antigens and exclude harmful ones.
Questions still open
- What is the mechanism by which inhibitory neoantigens accelerate tumor growth?
- Should all neoantigen vaccine trials incorporate empirical screening like ATLAS?
- Can inhibitory neoantigens be identified computationally to avoid the labor-intensive bioassay?
Common questions
What are inhibitory neoantigens and why are they dangerous?
How is ATLAS different from other cancer vaccine approaches?
Read the original research
An Empirical Antigen Selection Method Identifies Neoantigens That Either Elicit Broad Antitumor T-cell Responses or Drive Tumor Growth.
Cancer discovery, 11(3), 696-713
Citation
Lam, Hubert; McNeil, Lisa K; Starobinets, Hanna; DeVault, Victoria L; Cohen, Roger B; Twardowski, Przemyslaw; Johnson, Melissa L; Gillison, Maura L; Stein, Mark N; Vaishampayan, Ulka N; DeCillis, Arthur P; Foti, James J; Vemulapalli, Vijetha; Tjon, Emily; Ferber, Kyle; DeOliveira, Daniel B; Broom, Wendy; Agnihotri, Parul; Jaffee, Elizabeth M; Wong, Kwok-Kin; Drake, Charles G; Carroll, Pamela M; Davis, Thomas A; Flechtner, Jessica Baker. (2021). An Empirical Antigen Selection Method Identifies Neoantigens That Either Elicit Broad Antitumor T-cell Responses or Drive Tumor Growth.. Cancer discovery, 11(3), 696-713. https://doi.org/10.1158/2159-8290.CD-20-0377